KRAS and colorectal carcinoma: Although PI3K mRNA levels did not exhibit any statistically significant difference, a decreasing trend was shown after being treated with heteronemin or tetrac in both cell lines, and by combined treatment in HCT-116 cells (KRAS MT CRC).